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The induction of antigen-specific effectorT cells is driven by proper antigen presentation and
co-stimulation by dendritic cells (DCs). For this reason strategies have been developed to
instruct DCs for the induction of CD4+ and CD8+T cell responses. Since DCs are localized,
amongst other locations, in peripheral tissues such as the skin, new vaccines are aiming
at targeting antigens to DCs in situ. Optimal skin-DC targeting in combination with ade-
quate adjuvant delivery facilitates DC maturation and migration to draining lymph nodes
and enhances antigen cross-presentation and T cell priming. In this review we describe
what DC subsets populate the human skin, as well as current vaccination strategies based
on targeting strategies and alternative administration for the induction of robust long-lived
anti-cancer effector T cells.
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INTRODUCTION
Immature dendritic cells (DCs) patrol the tissues to sense for
pathogens. Recognition of pathogens through specific innate
receptors allows antigen uptake and processing for presentation
on MHC class I and II molecules, while DCs migrate to secondary
lymphoid organs. Upon entry in the lymph nodes, DCs display a
mature phenotype, characterized by high expression levels of co-
stimulatory molecules and the production of pro-inflammatory
cytokines. The presentation of antigenic peptides on MHC class
I or II molecules combined with the signals derived from mature
DCs allows the initiation of antigen-specific humoral and cellular
immune responses (Ueno et al., 2007). Besides triggering acti-
vating immune responses aiming at the clearance of pathogens,
DCs are also capable to down-modulate unwanted auto-immune
reactions by maintaining immune tolerance via the induction of
regulatory T cells (Maldonado and von Andrian, 2010). Con-
sequently, as DCs are able to induce both activating as well as
suppressive immune responses, this makes them ideal targets for
vaccination strategies against cancer or autoimmune disorders.
During the past years, extensive research has focused on the
development of DC-targeting vaccination strategies against can-
cer. First attempts focused on pulsing DCs ex vivo with tumor
antigens and maturation agents (Tacken et al., 2007). This strategy
involved the generation of DCs from monocytes or CD34+ precur-
sors and the subsequent re-injection into the patient to generate
effective T and B cell responses against the tumor. Although this
system is well tolerated by the patients and have shown modest
clinical responses (Galluzzi et al., 2012), there are limitations to ex
vivo culture and antigen-loading of DCs. Firstly, it has been shown
that ex vivo cultured DCs exhibited reduced migratory poten-
tial and secondly, the development of personalized vaccines is
costly and difficult to standardize. By comparison, higher objective
clinical response rates have been obtained by immunotherapies
based on adoptive transfer of tumor-specific T cells [either ex vivo
expanded tumor infiltrating lymphocytes (TILs) or T cells trans-
duced with high affinity TAA-specific TCR or chimeric antigen
receptors (CARs)] (Gattinoni et al., 2012; Restifo et al., 2012; Turtle
et al., 2012). The success of this type of immunotherapy is shown
to depend on the number and differentiation status of adoptively
transferred T cells (Gattinoni et al., 2005; Klebanoff et al., 2011).
Additionally, several studies point to improved anti-tumor effi-
cacy when the T cells are activated immediately prior to or directly
after adoptive transfer. The latter could be accomplished by co-
administration of a tumor-antigen vaccine (Overwijk et al., 2003;
de Witte et al., 2008a,b; Klebanoff et al., 2009). However, also this
therapy is very costly and since effective TILs seem to be restricted
to melanoma and genetically engineered T cells only possess mon-
oclonal specificity, targeting DCs directly in vivo therefore provides
an attractive alternative.
The goal of in vivo DC-targeting vaccines is twofold, accumu-
lating antigens to DCs in a cell-specific manner while promoting
antigen uptake, cross-presentation, and DC maturation. In order
to achieve this, knowledge on the selective expression of antigen-
uptake receptors on various DC subsets is required,as well as which
DC subsets has superior cross-presentation capacity. DCs express a
multitude of pattern recognition receptors, such as Toll-like recep-
tors (TLRs) and C-type lectins (CLRs). While TLRs play a crucial
role in pathogen recognition, the induction of DC maturation, and
the production of inflammatory cytokines, CLRs have been shown
to have a subset-specific expression pattern and are able to mediate
antigen uptake and cross-presentation. Already more than 10 years
ago, work from the group of Steinman showed that the CLR DEC-
205 mediated the uptake of ovalbumin coupled to a DEC-205
antibody, resulting in increased CD4+ and CD8+ T cell activation
(Bonifaz et al., 2002, 2004). Since then, the targeting of several
CLRs with antigens conjugated to monoclonal antibodies (mAbs),
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including mAbs against mannose receptor (MR), CLEC9A, DC-
SIGN, and Langerin, has been explored (Caminschi and Shortman,
2012). While some of these CLRs are not considered DC specific,
such as DEC-205 and MR, others such as DC-SIGN, CLEC9A,
and Langerin are expressed on specific DC subsets [myeloid DCs
(mDC), plasmacytoid DCs (pDCs), and Langerhans’ cells, respec-
tively]. Although several studies in search of the most efficient
cross-presenting DC subset have demonstrated the CLEC9A+
pDC as the most potent one in cross-presenting soluble antigen
compared to LC and mDC, it may still be that for certain glyco-
sylated antigens that target Langerin+ LC and DC-SIGN+ mDC,
these subsets might have similar potential as the CLEC9A+ pDC
to cross-present (Tel et al., 2012, 2013; Unger et al., 2012). In gen-
eral, it has become clear that only the simultaneous delivery of
CLR-targeting antigens together with a potent adjuvant will lead
to the generation of efficient CD4+ and CD8+ T cell responses,
especially in the context of anti-tumor immune therapies.
In addition, DC subsets present in the various tissues and lym-
phoid organs do not all express the same level and variety of CLRs
and not all DC subsets are equally potent in activating CD4+ and
CD8+ T cells. By deliberate selection of the right DC subset and/or
through targeting of CLRs specifically expressed by DC subsets, an
optimal induction of cellular immune responses (either immu-
nity or tolerance) can be achieved. Although a lot of data has
been accumulated on DC targeting strategies in in vivo systems
in mice, still little is known on the efficacy of DC-targeting vac-
cines in human skin. Here, we review recent knowledge on DC
subsets residing in the human skin, including their CLR and TLR
expression, capacity to cross-present antigens, and to respond to
adjuvants for migration to draining lymph nodes. Finally, new
developments on the strategies used to selectively deliver vaccines
to specific layers within the skin, as well as how to overcome poten-
tial side effects of the immune suppressive skin micromilieu will
be discussed.
DC SUBSETS: DIFFERENCES IN FUNCTION AND CLR AND TLR
EXPRESSION
The human skin has been classically divided in two main compart-
ments: the epidermis and the dermis. The epidermis is the outer
layer that provides the barrier function to the skin. Within the epi-
dermis frequently dividing keratinocytes are located, melanocytes,
which produce the pigment melanin, and LCs, which are the main
epidermis-resident antigen-presenting cell (APC) and are char-
acterized by the expression of the CLR Langerin (Figure 1). In
addition, T cells, mainly CD8+ T cells, can be found in the epider-
mis. Whereas the epidermis has a relatively simple histology, the
underlying dermis is anatomically more complex and accumu-
lates greater cell diversity. The dermis is rich in many specialized
immune cells, including dermal DCs, CD4+ T helper (Th) cells,γδ
T cells, and natural killer T (NKT) cells. Moreover, macrophages,
mast cells, fibroblasts, and nerve-related cell types are also present.
The dermis is drained by lymphatic and vascular conduits, through
which migrating cells can traffic.
In both human and mice, two main lineages of skin-resident
DCs are known: pDCs and the tissue-resident mDC. Steady-state
human skin contains four phenotypically and functionally distinct
subsets of DCs. Within the epidermis CD1ahigh LCs can be found,
whereas the CD1a+, CD14+, and CD141+ DCs (also known as
BDCA3+ DCs) are present within the dermis (Klechevsky et al.,
2008, 2009; Haniffa et al., 2012; Segura et al., 2012). The lat-
ter subset has recently been described in the dermis of human
skin as a rather efficient DC in the cross-presentation of antigen
(Haniffa et al., 2012). In addition, high expression levels of CCR7
coincided with superior migratory behavior of these DC (van de
Ven et al., 2011; Haniffa et al., 2012). Furthermore, LCs have also
been described as very efficient in the priming and cross-priming
of CD8+ T cells, whereas CD14+ dermal DCs (dDCs) are able
to induce the generation of follicular Th cells (Klechevsky et al.,
2008; Banchereau et al., 2012). The precise function of the CD1a+
dDCs is still poorly defined, although it has been shown that they
are capable of stimulating CD4+ T cell proliferation (Klechevsky
et al., 2009). It has also been shown that LCs are less responsive to
bacteria due to a lack of TLR2, TLR4, and TLR5 expression, but are
known to express TLR1, TLR3, TLR6, and TLR10, making them
suitable to respond to viruses (Angel et al., 2007; van der Aar et al.,
2007; Klechevsky et al., 2009). CD14+ dDCs express most of the
10 human TLRs, while CD1a+ dDCs seem to express all TLRs with
exception of TLR9 and TLR10 (Angel et al., 2007; van der Aar et al.,
2007). In contrast, the CD141+ DC expresses high levels of TLR3
and TLR10 and moderate expression of TLR1, TLR2, and TLR6
(Hémont et al., 2013). In response to polyI:C, this subset produces
inflammatory cytokines such as TNF-α and IL-1β (Haniffa et al.,
2012).
The four skin resident DC subsets can also be separated
based on their expression pattern of CLRs: the CD14+ dDCs
typically express DC-SIGN, DEC-205, DCIR, Dectin-1, and MR
(Klechevsky et al., 2009), whereas the CD1a+ dDCs can be dis-
tinguished based on the expression of MGL and low levels of MR,
DEC-205, and DC-SIGN (Unger and van Kooyk, 2011) (Figure 1).
In humans, LCs are the only cells that express Langerin. Addition-
ally, LCs also express DEC-205 at intermediate levels. In contrast,
the CD141+DC express the CLRs DEC-205 and CLEC9A, which is
described to be involved in the uptake of dead cells (Poulin et al.,
2010; Meixlsperger et al., 2013). Therefore, LCs could be exclu-
sively targeted via Langerin, whereas specific targeting of CD14+
dDCs should be possible via DC-SIGN.
TARGETING ANTIGENS TO DC SUBSETS THROUGH SPECIFIC
C-TYPE LECTINS
C-type lectins such as DEC-205 and CLEC9A have shown their
capacity to internalize antigen for presentation to CD4+ T cells
and cross-presentation for the induction of antigen specific CD8+
T cells. Often antibodies specific for these receptors have been
used for targeting purposes (Bonifaz et al., 2004; Caminschi et al.,
2008). In contrast, Langerin, MR, and DC-SIGN can be either tar-
geted using specific mAbs or using their natural ligands, since
for these receptors the glycan-binding profile has been deter-
mined (Holla and Skerra, 2011; Lee et al., 2011; Unger et al.,
2012). The use of glycans reports several advantages, such as
the relatively easy production of glycans in large scale and their
lower immunogenicity as compared to mAbs. The potential use
of glycan-based DC-targeting vaccines applied via the skin has
hardly been investigated. Often the cross-presenting capacity of
skin-resident DC subsets has been investigated, by analyzing the
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FIGURE 1 |Targeting skin APCs. (A) Representative immunofluorescence
staining of human skin using monoclonal antibodies against CD1a (green),
CD14 (red), and DC-SIGN (blue). Nuclei are stained with the nuclear dye
Hoechst (yellow). (B) Distribution of skin APCs according to their CD1a and
CD14 expression levels. (C) Frequency, CLR and TLR expression and function
of the four main skin APC subsets. (D) Standard needles do not allow skin
APC targeting, while different models of microneedles allow for the specific
targeting of dermal APCs and, in some cases, also LCs.
potency of DC subset to cross-present soluble antigen. In these
studies the CD141+ DC subsets have shown to have a supe-
rior cross-presenting capacity, whereas LCs, CD14+, and CD1a+
DCs do not have this potential. Conjugation of antigen to anti-
Langerin antibodies resulted in increased cross-priming of CD8+
T cells by LCs (Klechevsky et al., 2008). We have shown that
conjugation of the DC-SIGN binding Lewis-type blood antigens
(Leb or LeX) or an antibody recognizing DC-SIGN to liposomes
resulted in an enhanced uptake by DC-SIGN+ cells in vitro using
monocyte-derived DCs (Unger et al., 2012). Of note, there was no
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difference in uptake between the glycan-modified and the anti-
DC-SIGN modified liposomes. These findings demonstrate that
not all CLRs share the same preference for glycan-modified anti-
gen, and that they can be presented on multivalent carriers or as
small, single glycan-modified peptides. In addition, the distinct
expression of CLRs by various DC subsets allows specific targeting
to the desired DC type using glycan- or antibody-modified vaccine
components.
FUNCTIONAL CONSEQUENCES OF TLR ACTIVATION WITHIN
THE HUMAN SKIN
Although the targeting of antigens through DC-SIGN and Lan-
gerin has already been shown to result in enhanced CD4+ and
CD8+ T cell responses, early work derived from the group of
Steinman provided evidence that only in the presence of a potent
adjuvant, CLR-mediated DC targeting induced strong cellular
immunity in vivo instead of generating tolerance (Bonifaz et al.,
2002).
During the past years, research has focused on the identification
of suitable adjuvants to combine with intradermal skin vaccination
strategies (Alving et al., 2012; Schneider et al., 2012; Oosterhoff
et al., 2013). We, and others, have shown that, in general, intrader-
mal administration of soluble TLR ligands does not have major
effects on DC migration, maturation, and T cell stimulatory capac-
ity, especially not in relation to the effects that TLR ligands show on
in vitro generated monocyte-derived DCs (Schneider et al., 2012;
Oosterhoff et al., 2013). The discrepancy found on DC matura-
tion after TLR stimulation in vitro and in situ might be caused
by specific, local suppression within the skin microenvironment.
Consequently, to overcome this suppression, a strong adjuvant
should be administered simultaneous with the DC-targeting vac-
cine. Surprisingly, the effects of Aldara, a FDA-approved immune
response modifier skin cream containing 5% of the TLR7 ago-
nist imiquimod, has shown its potential to improve CD8+ T cell
responses in mice and patients when topically applied on the skin
(Zuber et al., 2004; Fenoglio et al., 2013). It will be interesting
to determine the maturation effects of the Aldara cream on the
population of APC in human skin, and the induction of CD8 T
cell responses in comparison to intradermal injection of soluble
R838 (imiquimod; TLR7). Selection of the appropriate adjuvant
in combination with an anti-tumor vaccine is therefore essential
to induce immunity and avoid tolerance. A more detailed knowl-
edge of the different immune responses induced by CLRs and their
interplay with TLRs is needed for the improvement of vaccination
strategies using CLR ligands. Separate from TLR ligands allowing
DC maturation and migration to the draining lymph nodes, also
injection of cytokines in the skin as immunostimulators, such as
GM-CSF has been investigated (van den Eertwegh et al., 2012;
Grotz et al., 2013).
THE IMPORTANCE OF THE ROUTE OF VACCINE
ADMINISTRATION
The specific route of administration is often determined by the
type of adjuvant present in the vaccine. In humans, vaccines
containing aluminum-based or oil-in-water adjuvants are admin-
istered intramuscular (i.m.) or subcutaneously (s.c.) (Figure 1).
Intradermal (i.d.) administration of these vaccines likely causes
local irritation, induration, skin inflammation, and granuloma
formation. The development of novel adjuvants such as synthetic
TLR ligands or cytokines facilitates the use of the i.d. route. Vac-
cination i.d. has shown significant advantages with respect to
dose-sparing and immunogenicity in comparison to other routes
(e.g., s.c., i.m., i.v.) (Kenney et al., 2004). This is likely due the pres-
ence of multiple DC subsets in the skin. Additionally, skin DCs are
generally more prone to become immunogenic than, for exam-
ple, mucosal DCs. However, i.d. vaccination using standard needle
and syringes is technically challenging and inaccurate administra-
tion of vaccines can even result in adverse side effects. Moreover,
vaccination using standard needle and syringe will deliver the vac-
cine at one spot. It has not been thoroughly investigated whether
simultaneous delivery at different/multiple spots leads to superior
responses. Simultaneous delivery could be facilitated by the use
of microneedle arrays. Microneedle arrays can go into the skin at
very low insertion forces and controlled depth, facilitating effective
delivery of vaccines.
Indeed, using solid metal microneedles that were coated with
an antigen-containing solution it was shown that within 2 h, 50%
of DCs that had emigrated out of murine ear explants were antigen
positive (del Pilar Martin et al., 2012). Moreover, compared with
s.c. vaccination, a single vaccination with influenza-vaccine coated
solid metal microneedles induced potent long-lived immunity and
improved protection against influenza virus (Koutsonanos et al.,
2011). A new generation of microneedles are “reservoir-integrated
skin interface devices” that allow microneedle-guided transport of
the vaccine while remaining inserted in the skin (van der Maaden
et al., 2012). Recently, the microneedle delivery techniques have
been broadened by the generation of nanoporous out-of-plane
microneedle arrays from ceramic material (Bystrova and Luttge,
2011). The ceramic nanoporous microneedles allow the investiga-
tion of a range of parameters related to delivery performance (e.g.,
cargo loading capacity, amount and arrangement of micronee-
dles, microneedle tip shape). The use of so-called out-of-plane
microneedle arrays allows a standardized and regulated delivery
of the vaccine to dermal DCs. The intrusion depth into the skin is
self-defined by the microneedle length. Notably, this approach also
facilitates targeting of the LCs, which is more difficult when using
i.d. injection using classic syringe/needles. Moreover, by varying
the amount and arrangement of microneedles on the array as well
as the microneedle tip shape, different skin DC subset(s) may be
triggered. The impact of such microneedle arrays on the efficacy
of skin DCs targeting and/or the induction of T-cell mediated
immunity has not been fully investigated yet.
As an alternative, polymeric dissolvable microneedle arrays
are being explored that release the vaccine into the skin but
dissolve within minutes leaving no residual sharps waste. Using
these polymeric dissolvable microneedles, 23% of the DCs in
draining lymph nodes were loaded with microneedle-applied anti-
gen 72 h later. Unfortunately, this study did not address whether
this method was superior in vaccine delivery to dermal DCs
than conventional immunization strategies (Zaric et al., 2013).
However, Sullivan et al. (2010) showed that vaccination of mice
against influenza using these dissolvable microneedles induced
enhanced protection compared with conventional i.m. vaccina-
tion. Also more recently it was demonstrated that microneedle
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array skin delivery systems of live adenovirus vaccines in mice
resulted in potent CD8+ T cell priming through stimulating
Langerin− DCs, indicating that, in this study, LCs were not the
best in inducing cross-presentation, but dermal DCs (Bachy et al.,
2013).
THE SKIN MICROMILIEU: AN IMMUNE SUPPRESSIVE
ENVIRONMENT?
The main constituent of the skin is keratinocytes. Similar to gut
epithelial cells, keratinocytes can sense pathogens and mediate
immune responses to discriminate between harmless commen-
sal organisms and harmful pathogens. Epidermal keratinocytes
express several TLRs, located either on the cell surface (TLR1,
TLR2, TLR4, TLR5, and TLR6) or in endosomes (TLR3 and TLR9)
(Begon et al., 2007; Lebre et al., 2007). In addition, TLR7 expres-
sion is induced through the triggering of TLR3 by double-stranded
RNA,which makes keratinocytes responsive to TLR7 agonists. TLR
expression by keratinocytes might be crucial for promoting skin
immune responses, as activation of these receptors on human ker-
atinocytes leads to a predominant Th1-type immune response and
to the production of type I interferons. In addition to antimicrobial
peptides, keratinocytes constitutively secrete, or induced to release,
numerous cytokines, including IL-1, IL-6, IL-10, IL-18, and TNFα.
Of particular interest with regard to the skin in health and disease
is the production of IL-1 by keratinocytes. In healthy skin, ker-
atinocytes constitutively synthesize both pro-IL-1α and pro-IL-1β
but cannot process them or secrete them in their active forms. Fol-
lowing exposure to stimuli such as UV irradiation, keratinocytes
process and release IL-1β through the activation of the inflamma-
some. Keratinocytes are also an important source of chemokines
and express chemokine receptors, and therefore can modulate an
immune response by attracting different cell types into the skin.
By expressing CC-chemokine ligand 20 (CCL20),CXC-chemokine
ligand 9 (CXCL9), CXCL10, and CXCL11 activated keratinocytes
selectively attract effector T cells to the skin during diseases or
recruit neutrophils or regulate the trafficking of Langerhans cell
precursors to the epithelium.
In contrast, TGFβ is a cytokine with anti-inflammatory prop-
erties that is produced by different cell types in the skin, such as
LC and keratinocytes. LC-produced TGF-β1 has been shown to
act in a autocrine/paracrine fashion and to maintain the LC in the
epidermis, as inferred from emigration of LC from the skin upon
abrogating TGF-β1 signaling (Bobr et al., 2012). These data suggest
that blocking TGF-β1 signaling (via anti-TGFβ-RI Abs or pharma-
cological inhibitors) might be beneficial to include in vaccines that
aim to induce antigen-specific CD8+ effector T cells by targeting
LC, such as in cancer. The other main producers of TGF-β1 in
the skin are keratinocytes. It has been shown that TGF-β1 levels
rise upon wounding of the skin or chronic psoriasis (Flisiak et al.,
2002, 2003; Wang et al., 2006), but also premalignant keratinocytes
express elevated levels of TGF-β1. The increased levels of TGF-
β1 were associated with enhanced LC migration and significantly
affected dermal DC composition: increased numbers of skin DCs
and pDCs had emigrated and were detected in skin-draining LN,
while the influx of blood-derived pDC and DC precursors into the
skin was highly increased.
FUTURE DIRECTIONS
A lot of knowledge has been gathered on the presence of different
human skin-resident APCs, at distinct locations. The expression
of innate receptors such as C-type lectins and TLR has been well
characterized, and four subsets have been identified individually
on their efficacy to mature, migrate, and cross-present antigen for
the induction of CD8+ T cells. Based on the expression of different
set of TLR and CLR it has been speculated that these APC subsets
(pDC and mDC) have a division of labor. Some subsets are crucial
in the recognition of soluble antigens, while others play a major
role in particulate recognition of glycosylated bacterial or viral
products. Although we are beginning to understand the function
of these APC subsets individually, we hardly have any knowledge
available on the function of these APC in situ in the human skin.
In particular how the suppressive network of keratinocytes may
imprint local APC as well as be involved in the inflammatory
activation and trigger APC to mature and migrate to draining
lymph node for T cell priming. Future vaccination strategies are
therefore important to reveal how we can optimally instruct this
skin-resident repertoire of APC in situ to overcome the suppressive
skin micromilieu, and activate them simultaneously (both mDC
and pDC) to induce robust antigen T cells responses.
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APPENDIX
KEY CONCEPTS
In vivo DC targeting
An interesting alternative to vaccination strategies based on ex
vivo culturing of DCs. Through in vivo DC targeting approaches,
vaccines are prepared to specifically reach DCs in their natural
micromilieau, and hypothetically benefit from the accumulation
of antigens in the most effective APCs, with high migratory
capacity and while ensuring proper cross-presentation and DC
maturation.
The four skin resident APC subsets differ in the expression pattern
of CLRs
While CD14+ dDCs express DC-SIGN, DEC-205, DCIR,
Dectin-1, and MR, CD1a+ dDCs can be distinguished
based on the expression of MGL and low levels of MR,
DEC-205, and DC-SIGN. On the other hand, LCs are
the only APCs that express Langerin. LCs also express
DEC-205. In contrast, CD141+ DCs express DEC-205 and
CLEC9A.
Advantages on the use of glycans to target CLRs on skin APCs
In contrast to other APC-specific receptors used in in vivo DC tar-
geting vaccination strategies, the natural ligands of CLRs are low
immunogenic, can be mass-produced by chemical methods, and
can be easily conjugated to the antigen of choice.
Choice of adjuvant
Several CLRs are able to elicit a signaling response that down-
modulates the activatory effect of TLRs. However, when higher
doses of adjuvants are provided, the net result of this finely reg-
ulated signaling system is activatory. Thus, the selection of the
appropriate adjuvant is essential for the success of a CLR-targeting
strategy.
Choice of administration route
The availability of novel TLR-specific powerful adjuvants and the
advances in needle engineering have allowed the development of
intradermal vaccination devices that allow lower antigen dosage
and higher immunogenicity compared to classic vaccination
administration routes.
Frontiers in Immunology | Immunotherapies and Vaccines June 2013 | Volume 4 | Article 157 | 8
